The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
Status:
Unknown status
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral
Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized
cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban,
rivaroxaban and dabigatran for oral anticoagulation in non-valvular atrial fibrillation
across Danish hospitals and cardiology clinics.